【摘要】 目的:以利培酮为对照,探讨齐拉西酮治疗精神分裂症的疗效和安全性。方法:将70例符合CCMD一3诊断标准的精神分裂症病人随机分为两组,分别给予齐拉西酮和利培酮治疗8周。于治疗前和治疗后2、4、8周末采用阳性症状和阴性症状量表(PANSS)评定临床疗效,副反应量表(TESS)评定副反应。结果:治疗8周后,两组疗效近似(P>0.05),齐拉西酮组和利培酮组的有效率差异无显著性(P>0.05);齐拉西酮组的副反应发生率低于利培酮组,但差异无显著性(P>0.05)。利培酮组锥体外系副反应明显高于齐拉西酮组(P<0.05)。结论:齐拉西酮对精神分裂症患者的疗效与利培酮相当,副作用较小。更多还原

【Abstract】 Objective: To investigate the clinical efficacy and side effects of zipraside with risperidone as a control in the treatment of schizophrenia.Methods:A tota1 of 70 cases meeting the criteria of CCM D-3 for schizophrenia were randomly assigned to two group treated with zipraside(zipraside group) or risperidone(risperidone group)for 8 weeks.The positive and negative symptoms scale(PANSS)and treatment emergent symptoms scale(TESS)were used to evaluate the efficacy and adverse effects before treatment and at the end of 2-,4-and 8-week treatment.Results:The therapeutic efficacy in zipraside group was similar to that in risperidone group(P>0.05),with no significant difference between the two groups(P>0.05).The incidence of adverse effects in zipraside group was lower than that in risperidone group,with no significant difference between the two groups(P>0.05),The incidence of extrapyramidal symptoms in risperidone group was significantly higher than that in zipraside group.Conclusion:Zipraside is as effective as risperidone in the treatment of schizophrenia with fewer side effects.更多还原